Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, J., Velez, L., Trevino, T.L., Grothey, A., Yaeger, R., Van Cutsem, E., Wasan, H., Desai, J., Ciardiello, F., Yoshino, T., Gollerkeri, A., Maharry, K., Christy-Bittel, J., Kopetz, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666642/
https://www.ncbi.nlm.nih.gov/pubmed/34896698
http://dx.doi.org/10.1016/j.esmoop.2021.100328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666642/
https://www.ncbi.nlm.nih.gov/pubmed/34896698
http://dx.doi.org/10.1016/j.esmoop.2021.100328

Ejemplares similares